TIPE2, a novel biomarker for clinical chronic kidney allograft rejection.

Tumor necrosis factor-a--induced protein 8-like 2 (TIPE2) has an essential role in immune homeostasis, yet the relationship between TIPE2 expression and allograft rejection has not been addressed. Dependent on clinical diagnosis, 96 kidney transplant recipients were divided into three groups, long-term survival group, acute rejection group (AR) and chronic rejection group (CR). Thirty-two healthy volunteers were used as a control group. The expression of TIPE2 in peripheral blood mononuclear cells (PBMC) and kidney biopsy samples was performed using reverse transcript-polymerase chain reaction, immunohistochemistry and immunofluorescence. The expression of TIPE2 in PBMC of CR group was significantly higher than that of the healthy control (P < 0.001), but TIPE2 expression in AR group was lower than that of control individuals (P < 0.05). The renal expression of TIPE2 in allograft tissue of CR was significantly lower and its expression in AR slightly lower than in normal kidneys. The positive correlation between TIPE2 expression in PBMCs and the CR of allo-kidney grafts indicates that detection of TIPE2 in the blood samples may be used as one of the diagnosis molecular markers in clinical monitoring kidney chronic rejection.